═══════════════════════════════════════════════════════════════
VERIFICATION REPORT
═══════════════════════════════════════════════════════════════

ARTIFACT: Medical Diagnostic Decision Support System
DATE: 2026-01-20
WORKFLOW VERSION: 12.1

───────────────────────────────────────────────────────────────
VERDICT
───────────────────────────────────────────────────────────────

VERDICT: REJECT
CONFIDENCE: HIGH
EVIDENCE SCORE: S = 9
EARLY EXIT: Yes — Phase 1

───────────────────────────────────────────────────────────────
KEY FINDINGS
───────────────────────────────────────────────────────────────

[F1] CRITICAL — The artifact claims both FDA Class III compliance and a continuous learning capability, which are mutually exclusive under current regulations. Class III devices require a new Pre-Market Approval (PMA) for any significant changes, making continuous learning as described infeasible.
     Quote: "FDA Class III medical device compliance" and "Continuous Learning Module"
     Location: Section 1.2, Section 4
     Pattern: FDA_LEARNING

[F2] CRITICAL — The system claims to be both deterministic for reproducibility and adaptive through continuous learning. A system that learns and updates its model cannot be deterministic over time, as the same input will yield different outputs before and after a model update.
     Quote: "Deterministic output for reproducibility" and "Incremental model update with new cases"
     Location: Section 2.2.2, Section 4.1
     Pattern: DETERMINISTIC_ADAPTIVE

[F3] CRITICAL — The artifact claims "99.9% sensitivity and 99.9% specificity" across "10,000+ disease conditions" based on a "Retrospective study on 100K cases". This implies an average of fewer than 10 cases per condition, which is statistically insufficient to validate such high accuracy claims, especially for rare diseases.
     Quote: "achieving 99.9% sensitivity and 99.9% specificity"
     Location: Section 1.1, Section 6.2
     Pattern: ACCURACY_WITHOUT_N

───────────────────────────────────────────────────────────────
METHODS EXECUTED
───────────────────────────────────────────────────────────────

Phase 1:
  □ #71 First Principles — Finding
  □ #100 Vocabulary Audit — Finding
  □ #17 Abstraction Laddering — Finding

Phase 2:
  (Skipped due to Phase 1 early exit)

Phase 3:
  (Skipped due to Phase 1 early exit)

───────────────────────────────────────────────────────────────
NOT CHECKED
───────────────────────────────────────────────────────────────

- Deeper algorithmic details: Not examined because the foundational claims are invalid.
- Implementation specifics (e.g., SHAP analysis, offline mode): Not examined due to critical architectural and regulatory contradictions.
- Usability and liability frameworks: Not relevant given the core system as described is not feasible.

───────────────────────────────────────────────────────────────
RECOMMENDATIONS
───────────────────────────────────────────────────────────────

If REJECT:
  1. Re-architect the system around a fixed, validated model that can achieve a specific FDA clearance (e.g., a Class II De Novo or Class III PMA). The "continuous learning" aspect must be redefined as a periodic, fully-validated, and re-submitted new version of the device.
  2. Fundamentally reconsider the claims of determinism vs. learning. Choose one. If learning is chosen, abandon claims of simple reproducibility and build a framework for managing model versioning and its clinical impact.
  3. Drastically revise accuracy claims to be statistically sound. This likely means focusing on a much smaller subset of diseases where sufficient validation data exists, or providing per-condition accuracy metrics that reflect the available evidence.

═══════════════════════════════════════════════════════════════
